Obsidian Therapeutics
OBX
Obsidian Therapeutics (OBX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Initiated Coverage | Outperform | $32.00 | Sep 22, 2026 |
| William Blair | Initiated Coverage | Outperform | — | Sep 9, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $43.00 | Aug 18, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $42.00 | Aug 5, 2026 |
Frequently asked questions
What is the latest analyst rating on OBX?
On Sep 22, 2026, Leerink Partners initiated coverage of Obsidian Therapeutics at Outperform with a price target of $32.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.